This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases. Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with continuous enrollment in the 6M baseline and 6M or 12M follow-up period were included. Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
In the matched cohorts, baseline characteristics were balanced; the mean age was 53 years, and 50% of patients were women. Compared to semaglutide initiators, dulaglutide initiators were more adherent (6M, 63.4% vs 47.8%; 12M, 54.4% vs 43.3%; both, P < 0.0001), more persistent on therapy (6M, 72% vs 62%, 12M, 55.5% vs 45.3%, both, P < 0.001), and had more mean days of persistence (6M, 145 vs 132, 12M, 254.3 vs 220.7; both, P < 0.001).
At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
这次回顾展,观察性队列研究使用来自三个IBMMarketScan研究数据库的行政索赔数据.数据来自2018年1月至2020年1月期间新开始使用杜拉鲁肽或司马鲁肽治疗的成年2型糖尿病患者(指标日期定义为最早填写日期),在6M基线期没有胰高血糖素样肽1受体激动剂使用的证据,纳入6M基线和6M或12M随访期的连续入组.杜拉鲁肽的发起者倾向得分匹配,以1:1的比例,每个6M和12M随访队列中的司马鲁肽发起者(26,284和13,837对,分别)。
在匹配的队列中,基线特征平衡;平均年龄为53岁,50%的患者是女性。与司马鲁肽引发剂相比,杜拉鲁肽引发剂更粘附(6M,63.4%对47.8%;12M,54.4%vs43.3%;两者,P<0.0001),更持久的治疗(6M,72%vs62%,12M,55.5%vs45.3%,两者,P<0.001),并且平均持续天数更多(6M,145vs132,12M,254.3vs220.7;两者,P<0.001)。
在6M和12M随访时,与匹配的赛马鲁肽引发剂相比,杜拉鲁肽引发剂具有更大的粘附性和更高的持久性。